Provided by Tiger Trade Technology Pte. Ltd.

AEON Biopharma

0.3577
+0.067723.34%
Volume:19.97M
Turnover:6.91M
Market Cap:17.84M
PE:-0.10
High:0.3799
Open:0.2980
Low:0.2903
Close:0.2900
52wk High:1.45
52wk Low:0.1772
Shares:49.88M
Float Shares:30.51M
Volume Ratio:1.52
T/O Rate:65.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5840
EPS(LYR):-3.9532
ROE:--
ROA:-141.53%
PB:-1.16
PE(LYR):-0.09

Loading ...

AEON Moves to Fully Acquire Struggling Footwear Subsidiary GFOOT via Share Consolidation

TIPRANKS
·
Apr 08

AEON Fantasy Lifts Full-Year Profit Outlook on Record Sales and FX Gains Despite ASEAN Pressure

TIPRANKS
·
Apr 06

Aeon receives additional notice related to NYSE American listing standards

TIPRANKS
·
Apr 06

AEON Biopharma grants CFO John Bencich 1.0 million inducement equity awards

Reuters
·
Apr 04

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

GlobeNewswire
·
Apr 04

AEON Biopharma gets NYSE American notice for failing stockholders’ equity listing standard

Reuters
·
Apr 04

AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards

GlobeNewswire
·
Apr 04

Aeon Credit Service Asia SEHK 900 Margin Compression Keeps Bearish Narratives Alive After FY 2026 Results

Simply Wall St.
·
Apr 01

AEON CREDIT Reports Fiscal Year Profit Surge to HK$468 Million

Stock News
·
Mar 31

AEON Credit Service (Asia) Declares Final Dividend for FY2025/26

TIPRANKS
·
Mar 31

AEON Biopharma Q4 EPS $(3.72)

Benzinga Earnings
·
Mar 31

AEON Biopharma FY25 net loss widens to $39 million

Reuters
·
Mar 31

Press Release: AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program

Dow Jones
·
Mar 31

AEON Stores Hong Kong to See Chairman and Non-Executive Director Retire at 2026 AGM

TIPRANKS
·
Mar 27

Aeon Biopharma announces FDA feedback after Type 2a meeting

TIPRANKS
·
Mar 25

AEON Biopharma Inc - to Request Bpd Type 2B Meeting With FDA in 2026 for Abp-450 Biosimilar

THOMSON REUTERS
·
Mar 25

AEON Biopharma Inc - FDA Supports AEON's Analytical Similarity Strategy Under 351(K) Biosimilar Pathway

THOMSON REUTERS
·
Mar 25

AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program

GlobeNewswire
·
Mar 25

AEON REIT Maps Out Growth Strategy Around Community Retail Assets

TIPRANKS
·
Mar 17

AEON REIT Posts Softer Earnings, Trims Core Payout but Maintains Total Distributions

TIPRANKS
·
Mar 17